ABIONYX Pharma Valuation

Is ABNXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABNXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ABNXP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ABNXP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABNXP?

Key metric: As ABNXP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ABNXP. This is calculated by dividing ABNXP's market cap by their current revenue.
What is ABNXP's PS Ratio?
PS Ratio	18.9x
Sales	€3.28m
Market Cap	€62.09m

ABNXP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.1x
Enterprise Value/EBITDA	-10.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ABNXP's PS Ratio compare to its peers?

The above table shows the PS ratio for ABNXP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14.9x
AREC Arecor Therapeutics	5.8x	35.2%	UK£28.3m
AVCT Avacta Group	7.9x	0.4%	UK£179.3m
TRX Tissue Regenix Group	1.6x	15.1%	UK£40.6m
BSFA BSF Enterprise	44.2x	n/a	UK£3.0m
ABNXP ABIONYX Pharma	18.9x	-17.7%	€62.1m

Price-To-Sales vs Peers: ABNXP is expensive based on its Price-To-Sales Ratio (18.9x) compared to the peer average (9.7x).

Price to Sales Ratio vs Industry

How does ABNXP's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.5x	21.0%	US$554.49m
TRX Tissue Regenix Group	1.6x	15.1%	US$50.88m
PBX ProBiotix Health	4.8x	n/a	US$12.88m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ABNXP is expensive based on its Price-To-Sales Ratio (18.9x) compared to the UK Biotechs industry average (17.2x).

Price to Sales Ratio vs Fair Ratio

What is ABNXP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABNXP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	18.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ABNXP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.5%

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

4.0%

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

-1.7%

-6.3%